Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2000-05-16
2002-03-19
Chan, Christina Y. (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C435S452000, C530S387100, C530S387900, C530S388100, C530S388210, C424S185100
Reexamination Certificate
active
06358711
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a human testin and to the use of these sequences in the diagnosis, treatment, and prevention of cancer and developmental disorders.
BACKGROUND OF THE INVENTION
LIM proteins are a family of proteins that share a common structural domain. The LIM motif is so named because it was first described in three proteins from
Drosophila melanogaster
designated L, I, and M. The LIM motif is a cysteine-rich region with a characteristic pattern: [C—X—X—C—X
17±1
—H—X—X—C]—X—X—[C—X—X—C—X
17±1
—C—X—X—C] (SEQ ID NO:4). LIM motifs form two loop structures and coordinate a zinc ion within each loop.
The LIM motif has been identified in a variety of proteins including transcription factors, cytoskeletal proteins, and signaling molecules. LIM proteins are involved in cell fate determination, growth regulation, and oncogenesis. At least twenty-three members of the LIM family have been described, from nematodes to humans. Some LIM proteins consist of one, two, or three repeats of the LIM motif and little else (LIM-only proteins). Others contain a LIM motif with a homeodomain (LIM-HD proteins) or a protein kinase domain (LIM-PK). LIM-PK inhibits the Ras oncogene-mediated differentiation of neural PC12 cells. LIM-HD proteins interact with DNA as well as bind to other proteins and are implicated in the control of differentiation of specific cell types. Studies in
C. elegans
demonstrated that LIM-HD proteins are involved in control of cell differentiation. Lin-11, a LIM-HD protein, controls the asymmetric cell divisions during vulval development, while Mec-3 is required for the differentiation of mechanosensory neurons (Way and Chalfie (1988) Cell 54:5-16; Freyd et al. (1990) Nature 344:876-879).
The LIM-only proteins have not been shown to bind DNA, although the LIM structure is similar to the zinc finger, a well-characterized DNA-binding domain. LIM-only proteins include the rat cysteine-rich intestinal protein (CRIP), the human RBTN1 and RBTN2 proteins, and the chicken zyxin protein (Higuchi et al (1997) Oncogene 14:1819-1825; Sanchez-Garcia and Rabbitts (1994) Trends Genet. 10:315-320; and Dawid et al (1995) C.R. Acad. Sci. 318:295-306). The genes for RBTN1 and RBTN2 are located on chromosome 11. Translocation mutations of chromosome 11 are associated with specific human T-cell acute leukemias. Transgenic expression of RBTN1 or RBTN2 produces leukemia and lymphoma in mice (McGuire et al (1992) Mol. Cell. Biol. 12:4186-4196; Fisch et al (1992) Oncogene 7:238 -2397).
A LIM-only protein, mouse testin, was recently cloned and characterized from a mouse testis germ cell library. Mouse testin contains three repeats of the LIM motif. Messenger RNA for mouse testin is widely distributed, with particularly strong signals in testis, kidney, and spleen (Divecha and Charleston (1995) Gene 156: 283-286).
The discovery of a new human testin and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of cancer and developmental disorders.
SUMMARY OF THE INVENTION
The invention features a substantially purified polypeptide, human testin (HTES), comprising a sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
The invention further provides a substantially purified variant of HTES having at least 90% amino acid identity to the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
Additionally, the invention provides a composition comprising a polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention further provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as an isolated and purified polynucleotide which is complementary to the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
The invention also provides an isolated and purified polynucleotide comprising a sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2, and an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide comprising the sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2. The invention also provides an isolated and purified polynucleotide which is complementary to the polynucleotide comprising the sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2.
The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. In another aspect, the expression vector is contained within a host cell.
The invention also provides a method for producing a polypeptide comprising a sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide encoding HTES under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.
The invention also provides a pharmaceutical composition comprising a substantially purified HTES having the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
The invention provides a purified antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:1. The invention also provides a composition comprising the antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:1. The invention further provides methods for preparing polyclonal and monoclonal antibodies which bind specifically to a polypeptide having the amino acid sequence of SEQ ID NO:1. The invention still further provides for a chimeric antibody, a single chain antibody, a Fab fragment, and a F(ab′)
2
fragment. The method yet still further provides for an antibody identified by screening a Fab expression library or a recombinant immunoglobulin library.
The invention provides a method for detecting a polypeptide having the amino acid sequence of SEQ ID NO:1 in a sample comprising combining the antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:1 with a sample under conditions to allow specific binding and detecting specific binding, wherein specific binding indicates the presence of polypeptide having the amino acid sequence of SEQ ID NO:1 in the sample. In different embodiments, the sample is from a subject with cancer of the uterus, prostate cancer, or breast cancer. The invention further provides a method for treating a cancer, the method comprising administering to a subject in need of such treatment an effective amount of an antibody which binds specifically to HTES.
The invention also provides a method for treating or preventing a developmental disorder, the method comprising administering to a subject in need of such treatment an effective amount of an antibody which specifically binds to HTES.
The invention still further provides a method of using an antibody to purify a polypeptide having the amino acid sequence of SEQ ID NO:1 from a sample by combining the antibody with a sample under conditions to allow specific binding and separating the antibody from the polypeptide, thereby obtaining purified polypeptide having the amino acid sequence of SEQ ID NO:1.
The invention also provides a method for detecting a polynucleotide encodi
Corley Neil C.
Guegler Karl J.
Lal Preeti
Chan Christina Y.
Huynh Phuong
Incyte Genomics Inc.
Incyte Genomics, Inc.
LandOfFree
Antibody to human testin and methods of making and using does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody to human testin and methods of making and using, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody to human testin and methods of making and using will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2862081